Skip To Main Content
Reshma Ramachandran on Muck Rack

Reshma Ramachandran

As seen in: CNN, Medium, MSN, The New York Times, Washington Post Opinions, Yahoo Canada, Yahoo News New Zealand, Aol, Los Angeles Times, PLOS and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Reshma

Contact Reshma, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Online Prescribing of GLP-1 Receptor Agonists

|
By Ashwin Chetty, Alissa Chen, Joseph Ross, Reshma Ramachandran
| JAMA: Journal of the American Medical Association Verified
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely available through online sellers, primarily for weight management, with nearly 20% of adults taking a GLP-1 RA obtaining prescriptions online.1,2 Availability of online GLP-1 RAs has been driven by the rise of compounded versions sold through telehealth platforms partnered with compounding pharmacies.2,3 Compounded GLP-1 RAs contain the same active ingredients but different inactive ingredients as branded GLP-1 RAs and are not...
Open in Who Shared Issue with article?

Commercial Price Variation for Common Dermatologic Procedures

|
By Ravi Dhawan, Joshua J. Skydel, Reshma Ramachandran, Joseph Ross, Howa Yeung, Joshua D. Wallach, Chelsea Deitelzweig
| JAMA Network Verified
In the US, demand for dermatologic procedures has increased over recent decades, driven by the aging population and higher incidence of skin cancer and chronic skin conditions.1 Procedure prices have also increased, potentially associated with market consolidation and private equity investment in dermatology practices.2 Despite concerns about affordability,2 with patients facing different out-of-pocket costs for the same procedures depending on insurance status and location,3 little is known...
Open in Who Shared Issue with article?

Politics, Science, and the Future of FDA Drug Regulation: FDA’s Review of Mifepristone REMS as a Litmus Test

|
By Reshma Ramachandran
| JAMA: Journal of the American Medical Association Verified
On September 19, 2025, US Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr and US Food and Drug Administration (FDA) Commissioner Martin Makary announced that HHS would be conducting “a study on the safety of the current [Risk Evaluation and Mitigation Strategy (REMS)]” for mifepristone to “determine whether modifications are necessary.” This announcement came in response to a letter from the attorneys general of 22 states, seeking a review of the mifepristone REMS.
Open in Who Shared Issue with article?
See all 122 licensed articles (149 Total)